Deals
Bid & Ask: The Deals of the Week
This article is for subscribers only.
1. Bristol-Myers Squibb will pay about $2.5 billion for biopharmaceutical company Inhibitex to improve its position in the market for hepatitis C drugs, which may reach $20 billion by 2020.
2. Raymond James Financial has agreed to buy Regions Financial’s Morgan Keegan brokerage unit, a top underwriter of U.S. municipal bonds, for $930 million.